Eli Lilly’s pill lagged behind Novo Nordisk in its first week. Why did the stock rise? – Investor’s Business Daily & more related News Here
Eli Lilly’s pill lagged behind Novo Nordisk in its first week. Why did the stock rise?investor’s business daily Eli Lilly just got some good news about its weight loss pillWSJ ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundaio (orfoglipron) to date, confirms its cardiovascular and overall safety profile as well as consistent improvements in…
